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Introduction: Rheumatoid arthritis (RA) is a disease characterized by inﬂammation of the
synovial membrane. Several authors have investigated the role of positron emission tomo-
graphy (PET) with ﬂuorine-18 ﬂuorodeoxyglucose (18F-FDG) in RA.
Objectives: To systematically review the current literature on the role of 18F-FDG PET in
the  diagnosis, determination of disease activity and assessment of treatment response in
patients with RA.
Methods: Searches were conducted in Medline, Cochrane Library, Lilacs, Pubmed and Scopus
in  Portuguese, English and Spanish languages, using the keywords «rheumatoid arthritis»,
«synovitis»,  «FDG», «PET», «glycolytic metabolism» and «disease activity».
Results: One hundred and forty-two articles were initially identiﬁed, of which only 40 were
related directly to the subject. Twelve original articles and three case reports that met the
inclusion criteria were selected.
Discussion: The presence of activated macrophages and ﬁbroblasts in pannus are respon-
sible for the intense periarticular uptake of 18F-FDG. The uptake patterns do not allow the
differential diagnosis with other arthritides. The uptake intensity and the number of joints
involved are metabolic parameters of disease activity that correlate well with the compos-
ite  indices. Longitudinal studies of PET have proven useful in assessing the response to
treatment with anti-TNF. When performed early, PET can predict the therapeutic response.
Conclusion: Although the actual role of this new technique for the investigation of RA is not
yet  established, 18F-FDG PET is a promising tool in determining the activity and predictionof  response to treatment of patients with RA.
© 2014 Elsevier Editora Ltda. All rights reserved.DOI of original article: http://dx.doi.org/10.1016/j.rbr.2014.07.002.
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E-mail: daltonanjos@unb.br (D.A. dos Anjos).
http://dx.doi.org/10.1016/j.rbre.2014.07.003
2255-5021/© 2014 Elsevier Editora Ltda. All rights reserved.
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Tomograﬁa  por  emissão  de  pósitrons  com  FDG-18F  na  avaliac¸ão  de
pacientes  com  artrite  reumatoide  –  revisão  sistemática
Palavras-chave:
Tomograﬁa por emissão de
pósitrons (PET)
Flúor-18 (FDG-18F)
Artrite reumatoide
r  e  s  u  m  o
Introduc¸ão: a artrite reumatoide (AR) é uma doenc¸a caracterizada pela inﬂamac¸ão da mem-
brana  sinovial. Diversos autores têm investigado o papel da tomograﬁa por emissão de
pósitrons (PET) com ﬂúor-18 (FDG-18F) na AR.
Objetivos: REVISÃO sistemática da literatura atual sobre o papel do PET com FDG-18F no
diagnóstico, determinac¸ão da atividade da doenc¸a e avaliac¸ão da resposta ao tratamento
em  pacientes com AR.
Métodos: Foram realizadas buscas nas bases de dados Medline, Biblioteca Cochrane, Lilacs,
Pubmed e Scopus nos idiomas português, inglês e espanhol, utilizando as palavras-chave
«artrite reumatoide», «sinovite», «FDG», «PET», «metabolismo glicolítico» e «atividade da
doenc¸a».
Resultados: Cento e quarenta e dois artigos foram inicialmente identiﬁcados, dos quais
apenas 40 relacionavam-se diretamente ao tema. Foram selecionados 12 artigos originais e
três  relatos de caso que preenchiam os critérios de inclusão.
Discussão: A presenc¸a de ﬁbroblastos e macrófagos ativados no pannus é responsável
pela intensa captac¸ão periarticular de FDG-18F. Os padrões de captac¸ão não permitem
o  diagnóstico diferencial com outras artrites. A intensidade de captac¸ão e o número de
articulac¸ões  envolvidas são parâmetros metabólicos de atividade da doenc¸a que apre-
sentam boa correlac¸ão com os índices compostos. Estudos longitudinais de PET têm se
mostrado úteis na avaliac¸ão da resposta ao tratamento com anti-TNF. Quando realizado
precocemente, PET pode predizer a resposta terapêutica.
Conclusão: Embora o real papel dessa nova técnica na investigac¸ão da AR ainda não esteja
estabelecido, PET com FDG-18F é uma ferramenta promissora na determinac¸ão da atividade
e  na predic¸ão de resposta ao tratamento de pacientes com AR.
©  2014 Elsevier Editora Ltda. Todos os direitos reservados.
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[ntroduction
heumatoid arthritis (RA) is a systemic autoimmune disease
haracterized by chronic inﬂammation of the synovial mem-
rane. Its prevalence in adults is up to 1%. When not properly
reated, RA can lead to osteoarticular destruction and func-
ional limitations, with marked socioeconomic impact.1
Rheumatoid synovitis shows intense inﬂammatory inﬁl-
rate associated with neovascularization and proliferation of
he synovial membrane. The thickened and inﬂamed synovial
embrane, also known as pannus, is directly linked to bone
nd joint destruction.2
The diagnosis of RA in its early stages (up to 12 months
fter the onset of the ﬁrst symptoms) is of paramount impor-
ance for a successful treatment. The establishment of an
dequate treatment in this period, also known as “window
f therapeutic opportunity” may prevent or limit considerably
he consequences of long-term RA.3,4 However, this diagnosis
n an early stage can present difﬁculties. Multiple conditions
ay clinically manifest themselves in a similar manner to RA,
ncluding infectious diseases, systemic rheumatic diseases,
pondyloarthritis, arthritis by crystal deposition, endocrine
nd neoplastic diseases.1,3,4Laboratory tests, such as those for inﬂammatory activity
erythrocyte sedimentation rate [ESR] and C-reactive protein
CRP]) are not speciﬁc, and rheumatoid factor (RF) may beabsent in more  than 30% of patients in the early phase of the
disease.5 The preesence of anti-protein and anti-citrullinated
peptides (ACPA) antibodies, including anti-citrullinated cyclic
peptide (anti-CCP) antibody, is quite speciﬁc, but its sensitivity
is limited (70-75%).[1.3]
Methods of diagnostic imaging such as conventional radio-
graphy have been used to aid in the diagnosis of early RA,
but usually these techniques detect bony and cartilaginous
structural changes that occur late in natural history of the dis-
ease. Ultrasonography (US) and magnetic resonance imaging
(MRI) have also been employed, and MRI shows great potential
for determining the thickness of the synovial membrane and
in detecting bone marrow edema, being considered by many
authors as the gold standard (in terms of imaging procedures)
for the diagnosis of synovitis.1,3,6
Despite many  advances in understanding the pathophysi-
ology, diagnosis and treatment of RA, the current prognostic
and diagnostic (clinical, laboratory and radiographic) indica-
tors have limited value for early diagnosis and for establishing
individual prognosis.3,7
The delay of several weeks to establish the diagnosis in
patients with arthritis deprives those with RA from an ade-
quate treatment in the therapeutic window of opportunity.
In this context, other diagnostic strategies have been studied
8using new diagnostic imaging technologies now available.
Positron emission tomography, also called PET, is a widely
used tool in oncology. Neoplastic cells exhibit an exuberant
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glycolytic metabolism and, therefore, consume great quan-
tities of glucose. PET images of cancer patients demonstrate
intense uptake of radiolabeled ﬂuorine-18 ﬂuorodeoxyglucose
(18F-FDG) by malignant tumors and their metastases.9
18F-FDG is a glucose analogue linked to a radioactive
isotope, ﬂuorine-18. This molecule behaves similarly to glu-
cose, being avidly taken up by cells with intense glycolytic
metabolism. It has long been known that infectious and
inﬂammatory processes also exhibit high uptake of 18F-FDG.
The increased expression of glucose transporter proteins
(GLUT types I and III) by membranes of leukocytes present
in inﬂammatory sites, mainly neutrophils and macrophages,
leads to this uptake. This pathophysiological mechanism
explains why the intensity of 18F-FDG uptake is directly pro-
portional to the intensity of the activity of inﬂammatory
processes.10–12
Therefore, 18F-FDG PET is able to directly detect and
quantify articular and extra-articular sites of increased
inﬂammatory activity. That puts this tool at an advantage
over other diagnostic imaging methods, which detect indirect
changes of RA, such as erosions (radiography), increased blood
ﬂow (Doppler), increased thickening of the synovial mem-
brane (ultrasonography), the presence of bone edema (MRI)
or increased osteoblastic activity (bone scan).
The ﬁrst reports of the use of PET in RA are dated from 1995.
Researchers at Massachusetts General Hospital in Boston
reported the occurrence of strong 18F-FDG uptake in two
patients diagnosed with RA and with clinically active synovitis
in their wrists.13 Since then, the utility of 18F-FDG PET in the
management of RA has been investigated by several authors.
Purpose
The purpose of this study was to conduct a systematic review
of the current literature on the role of 18F-FDG PET in the
diagnosis, assessment of disease activity and monitoring the
efﬁcacy of treatment with disease-modifying antirrheumatic
drugs (DMARDs) in patients with RA.
Methods
In the period from March to June 2011, searches were con-
ducted through the following databases: Medline (1980-2012),
The Cochrane Library, Lilacs, Pubmed (1980-2012) and Scopus
in Portuguese, English and Spanish languages. The key-
words used were “rheumatoid arthritis” (artrite reumatoide),
“synovitis” (sinovite), “FDG”, “PET”, “glycolytic metabolism”
(metabolismo glicolítico) and “disease activity” (atividade da
doenc¸a).
Inclusion criteria were: original articles and case reports
that addressed the role of PET in rheumatoid arthritis and that
contained an adequate description of the materials, methods
and results achieved. Review articles, letters to the editor and
editorials were excluded.The title and abstract of the articles obtained in the initial
search were reviewed by two independent observers in order to
identify those that were relevant. A review of the full version
was performed on all those papers which met  the inclusion 0 1 4;5 4(6):474–482
criteria; and the references of these articles were analyzed in
order to draw attention to additional sources. For the purposes
of this study, were considered the papers selected after mutual
agreement of the two observers.
From the manuscripts selected, the following data were
observed: type of study, sample size, tools used, statistical
analysis and results.
Results
One hundred and forty-two articles were initially identiﬁed
in the databases mentioned, of which only 40 were related
directly to the topic searched. Of these, 14 were excluded for
being review articles, six for not including patients with RA,
four because they did not contain an adequate description of
materials and methods, and one because it did not use 18F-
FDG as radiotracer (Table 1). The 12 selected original articles
were classiﬁed by the authors as experimental studies, diag-
nosis studies, assessment of disease activity, and assessment
of treatment response. Table 2 summarizes the types of stud-
ies, the samples analyzed, the main technical characteristics,
clinical indices and other diagnostic methods used by the dif-
ferent articles, as well as their primary endpoint. Three case
reports were also included.
Experimental  studies
Experimental studies in animals and cell cultures have
investigated the pathophysiological mechanism involved in
periarticular uptake of 18F-FDG in patients with RA. Matsui
et al.14 used an animal model (rats). Arthritis was induced
by intradermal injection of bovine collagen. Rats were sac-
riﬁced immediately after performing PET images. Histology
and macroautoradiography of joints with arthritis were com-
pared to PET images. It was observed that areas of marked
uptake of 18F-FDG corresponded to areas of pannus and bone
destruction; on the other hand, moderately high uptake areas
were represented by hyperplasia of synovial layer cells and
by the presence of inﬂammatory inﬁltrate. Neutrophils and
macrophages were the predominant cells in these sites.
The authors also conducted an in vitro assay to deter-
mine 3H-FDG uptake by neutrophils, macrophages, ﬁbroblasts
and T cells exposed to certain pro-inﬂammatory cytokines
(TNF, IL-1 and IL-6). The 3H-FDG uptake by macrophages was
higher when stimulated by TNF versus IL-1 or IL-6. Fibro-
blasts exhibited a more  intense uptake than that observed in
macrophages, especially in response to stimulation by TNF or
IL-1. In contrast, no increase in 3H-FDG uptake was observed
in response to inﬂammatory cytokines in neutrophils and T
lymphocytes. These results suggest that the glycolytic hyper-
metabolism observed in joints of patients with RA is closely
related to the presence of pannus and to the inﬁltration of
activated macrophages and ﬁbroblasts.14
Thus, there is some pathophysiological substrate to explain
the avidity for labeled glucose by inﬂammatory cells present
18in the pannus. Such observations justify why F-FDG PET is
a method that directly detects the sites of RA activity. The
changes identiﬁed in PET images reveal the protagonist of the
pathophysiology of RA, which is the inﬂammation of the
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Table 1 – Selection process of studies according to inclusion and exclusion criteria.
Number of studies Type of study Selection criteria Status after selection process Total
12 Original article Met the inclusion criteria Inclusion 15
3 Case Report Met the inclusion criteria
14 Review article Review on the subject Exclusion 25
6 Original article Patients with RA not
included
4 Original article Materials and methods
were not described
adequately
1 Original article The glucose analog
(18F-FDG) not used as a
radiotracer for PET
RA, rheumatoid arthritis; PET, positron emission tomography.
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eynovial membrane. This knowledge has led several
esearchers to examine 18F-FDG PET as a method capable of
iagnose and demonstrate the activity of AR.
iagnostics
nﬂammatory arthritis and prolonged morning stiffness, asso-
iated with the presence of rheumatoid factor and other
ositive serum autoantibodies, and elevated inﬂammatory
ctivity tests favor the diagnosis of RA.1,3 However, often the
linical and laboratory manifestations are not typical. For this
eason, RA diagnosis has been based on pre-established clini-
al and laboratory criteria.15 Some authors have evaluated PET
s a tool in the differential diagnosis of arthritides.
Okabe et al.16 attempted to establish speciﬁc patterns of
8F-FDG uptake for RA able to differentiate this disease from
ther arthritides. Seventy patients with arthritis, 30 with RA,
ere included in a study with the aim to establish a pat-
ern of distribution of 18F-FDG. Ninety percent of patients
ith RA exhibited polyarticular hypermetabolism. However,
ther diseases also demonstrated this pattern of polyarticular
ypermetabolism, such as mixed connective tissue disease,
ystemic sclerosis and RS3PE syndrome (Remitting Seroneg-
tive Symmetrical Synovitis with Pitting Edema syndrome).
he atlantoaxial involvement was unique to patients with RA.
ome sites of hypermetabolism were characteristic of other
iseases, such as sacroiliac joint uptake in patients with anky-
osing spondylitis; liver, spleen and bone marrow increased
ptake in patients with adult Still’s disease; and arterial hyper-
etabolism in patients with polymyalgia rheumatica.
It should be noted that sites of extra-articular activity of AR
ay also exhibit hypermetabolism, such as lymph nodes and
ubcutaneous nodules17,18 and this subject was not addressed
y Okabe et al.;16 this could have contributed to the differen-
iation of arthritides (Fig. 1).
Elzinga et al.19 compared PET images in patients with
A (n = 17), osteoarthritis (n = 6), and ﬁbromyalgia (n = 5). As
ight be expected, patients with ﬁbromyalgia showed noreas of articular hypermetabolism. The number of hyper-
etabolic joints in patients with RA (88) was signiﬁcantly
igher than in patients with osteoarthritis (12) (P < 0.001). How-
ver, uptake intensity was not statistically different betweenthe two groups. This indicates that PET does not work ade-
quately as a tool for the differential diagnosis of these
diseases.
Assessment  of  disease  activity
The activity of RA can be measured by several clinical, lab-
oratory and radiological parameters. The composite indices
of disease activity are the most used and accepted among
rheumatologists. Methods of diagnostic imaging have been
reserved for speciﬁc cases.3,6
There are several studies relating the ﬁndings of PET
scans with indices of disease activity and other methods
of diagnostic imaging, such as ultrasonography (US) and
magnetic resonance imaging (MRI). Roivainen et al.20 demon-
strated a good correlation between intensity of 18F-FDG uptake
(standard uptake value [SUV]) with the volume of the syno-
vial membrane in 10 patients with clinically active synovitis.
Palmer et al.21 found a good correlation between SUV and
the volume of pannus which was enhanced under the para-
magnetic contrast fat-suppressed weighted MRI in 12 patients
with arthritis.
Beckers et al.22 compared the ﬁndings of PET scans with
clinical, laboratory and ultrasonographic parameters of RA. A
prospective study was conducted including 21 patients with
clinically active RA (ACR criteria 1987) using 18F-FDG PET. The
mean DAS28 was 7.4 (5.2-8.5) and mean SDAI was 60.2 (34.9-
75.5). All participants were not taking any DMARDs for at least
two months. Thirteen controls with no history of joint pain
were included in the study. PET was negative in all controls.
Of the 356 joints evaluated, 225 (63%) were positive on PET
studies. The amount of metabolically positive joints was lower
than the number of painful (266% vs. 75%) or swollen (282%
vs. 79%) joints and higher than the number of sonographic-
positive joints (199% vs. 56%). PET- and US-positive joints
(n = 27) had the mean thickness of the synovial membrane
signiﬁcantly higher (8.2 ± 0.9 mm)  than PET-positive and US-
negative joints (n = 6) (2,9 ± 0.5 mm).  A statistically signiﬁcant
correlation (p ≤ 0.05) between PET and all clinical parameters
analyzed was observed, except for the duration of morning
stiffness and for the assessment of functional capacity (HAQ).
The correlation among the number of PET-positive joints and
478
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Table 2 – Types of study, analyzed samples, main technical characteristics, clinical indices and other imaging methods used.
Author and
reference
Study Design Number of
participants
Number of
controls
Technical
procedure
used
Joints
evaluated by
patient
Other clinical
indices or diagnostic
methods
Primary
Outcome
Matsui et al.15 Experimental
study
5  4 PET - Macroautoradiography,
Histology
To  Compare PET with
macroautoradiography and histology
Okabe et al.16 Retrospective
clinical study
72 patients
(30 with RA)
- PET or PET/CT 19 - Diagnosis
Elzinga et al.19 Crossover
clinical study
14 with RA, 6
with OA
5  with FM PET 22 - Diagnosis
Palmer et al.21 Prospective
clinical study
12 with UA - PET 1 MRI Assessment of disease activity
Roivanen et al.20 Prospective
clinical study
2 with RA, 6
with UA, 1
with AS, 1
USA
-  PET 1 Contrast-
enhanced
MRI
Assessment of disease activity
Beckers et al.22 Prospective
clinical study
21 with RA 13 without
arthralgia
PET  12 or 22 US, SDAI, DAS28 Assessment of disease activity
Goerres et al.23 Prospective
clinical study
7 with RA - PET 28 DAS28, RDAI Assessment of disease activity
Kubota et al.24 Retrospective
clinical study
18 with RA - PET/CT 13 CRP, joint count Assessment of disease activity
Beckers et al.25 Cohort study 16 with RA - PET 1 US, MRI, CRP,
MMP-3
Assessment of treatment response
Okamura et al.26 Cohort study 22 with RA - PET/CT 12 US, MRI, DAS28,
DAS28-CRP, ESR,
CRP, MMP-3, RF
Assessment of treatment response
Elzinga et al.27 Exploratory
study
16  with RA - PET 12 CRP, ESR, MHAQ,
VAS
Assessment of treatment response
Sato et al.29 Prospective
clinical study
6 with RA - PET 2 DAS28, joint
count, ESR, CRP
Assessment of treatment response
RA, rheumatoid arthritis; OA, osteoarthritis; UA, undifferentiated arthritis; AS, ankylosing spondilitis; USA: undifferentiated spondyloarthritis; FM: ﬁbromyalgia; PET, positron emission tomography;
PET/CT, positron emission tomography with computed tomography; US, ultrasonography; MRI, magnetic resonance imaging, SDAI, simpliﬁed disease activity index; DAS28, disease activity score;
RDAI, rheumatoid arthritis disease activity index; CRP, C-reactive protein; MMP-3, matrix metalloproteinase-3; RF, rheumatoid factor; MHAQ, modiﬁed health assessment questionnaire; VAS, visual
activity score.
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Figure 1 – 18F-FDG PET of a female patient, 28 years old, complaining of symmetrical polyarthralgia, especially involving
hands and wrists and associated with prolonged morning stiffness. Laboratory tests revealed an ESR = 81 mm,  positive
rheumatoid factor (40.2 IU/mL) and an anticitrullinated peptide antibody strongly positive (82.5 IU/mL). The
three-dimensional reconstruction images (a, b, c) show high uptake in shoulders, wrists, metacarpophalangeal and
proximal interphalangeal joints of the hands and hips. Tomographic images of PET (d, g), CT scans (e, h) and PET/CT (f, 1)
showing intense hypermetabolism in bilateral axillary and pelvic lymph nodes (personal ﬁle).
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4omposite indices of the disease activity (DAS28 and SDAI) was
onsidered signiﬁcant (r = 0.90, P < 0.0001).
The analysis of these results suggests that the metabolic
ctivity of synovitis demonstrated by 18F-FDG PET can reﬂect
isease activity with a good correlation with DAS28 and SDAI.
owever, the small number os patients and the prevalence of
A patients with high disease activity in this study limit its
onclusions.
Goerres et al.23 proposed a visual score to quantify metabol-
cally active joints with PET. Seven patients with DAS28 ≥
.2 were included. An index of zero to 4 (zero for no uptakeand 4 for a marked uptake) was assigned to each of the
28 joints usually assessed by composite indices of disease
activity. The Spearman test showed a signiﬁcant correlation
between visual scoring by PET and DAS28. PET also revealed
sites of extra-articular (tendons and bursae) uptake in six
of seven patients. However, once again the small number of
patients included did not allow any extrapolation of these
ﬁndings.
Kubota et al.24 used PET scan with a focus on large joints.
Eighteen RA patients underwent 18F-FDG PET/CT to study
the metabolism of 13 joints (atlantoaxial, shoulders, elbows,
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wrists, carpals, hips and knees). PET/CT is a combination of
functional positron emission tomography equipment and a
computed tomography. Four patients were in clinical remis-
sion and 14 presented with clinically active RA. A modiﬁed
Goerres et al.23 score was used. The number of affected
joints and the total score of PET were signiﬁcantly differ-
ent among patients in remission and with active RA. There
was also a positive linear correlation between the total score
with PET and serum levels of CRP (r = 0.658, P = 0.003). Five
patients (28%) showed hypermetabolism in the atlantoaxial
joint. The presence of hypermetabolic axillary lymph nodes
was correlated with the superior limbs joints uptake (r = 0.731,
P = 0.000004).
Monitoring  treatment  response
The treatment with synthetic DMARDs has low cost. How-
ever, biological DMARDs have high cost and cause numerous
adverse effects. In this context, 18F-FDG PET has been used as
an attempt to discriminate whose patients can beneﬁt from
this type of treatment. Beckers et al.25 compared 18F-FDG PET
with contrast-enhanced MRI  and US in the treatment response
evaluation. Sixteen patients with active RA underwent whole-
body PET, contrast-enhanced MRI  and US of one knee (i.e.,
the joint referred to by patients as that with more  severe
pain) before and after four weeks of treatment with anti-
TNF (drug not speciﬁed by the authors). Metabolically positive
knees showed greater synovial thickness and a more intense
paramagnetic contrast enhancement. There was good correla-
tion between the intensity of 18F-FDG uptake (SUV), synovial
thickness with US and enhancement by paramagnetic con-
trast with MRI. After four weeks of treatment with anti-TNF,
a signiﬁcant decrease in SUV and in paramagnetic contrast
enhancement occurred, but without a signiﬁcant reduction in
synovial thickness. These data show that the response to bio-
logical treatments can be demonstrated by PET images with
respect to the metabolic aspect, before the observation of a
signiﬁcant reduction in synovial thickness by ultrasonogra-
phy or MRI  studies. However, of all possibly affected joints
in these 16 patients, the study only evaluated a large joint
(knee). This occurred due to a technical limitation of contrast-
enhanced MRI, which is a method that studies only one joint
area at a time, spending 30-40 minutes for each region. PET
shows great advantage in this regard, since it can assess
all joints of the body in a single examination, with similar
duration.
Okamura et al.26 studied 22 patients with poor response
to synthetic DMARDs, including methotrexate, and with indi-
cation for treatment with biologic DMARDs (etanercept in 16
and inﬂiximab in 6). All patients underwent 18F-FDG PET/CT at
baseline and six months after the initiation of therapy. DAS28,
DAS28-CRP, ESR, CRP, matrix metalloproteinase-3 (MMP-3) and
RF were determined on the same days of PET/CT. Patients
had moderate to high RA activity (mean DAS28: 5.29 ± 1.01;
minimum: 3.47 and maximum: 6.95). All clinical, laboratory
and metabolic parameters showed signiﬁcant decrease after
six months of treatment (mean DAS28: 3.81 ± 0.86, minimum:
2.21 and maximum: 5.33). There was good correlation among
values of SUV, DAS28 and DAS28-CRP. The decrease in SUV
also correlated with the decrease in values of DAS28 and 0 1 4;5 4(6):474–482
DAS28-CRP. These results show that PET can be an alternative
method for objectively measuring disease activity and deter-
mining the response to therapy with anti-TNF in a relatively
simple and straightforward manner and with good correlation
with the indices more  commonly used by rheumatologists for
such purposes.
Elzinga et al.27 investigated the potential of 18F-FDG
PET to predict the therapeutic response to inﬂiximab. Six-
teen patients with at least two swollen or painful joints
(metacarpophalangeal and/or wrists) were enrolled for treat-
ment with subcutaneous injections of inﬂiximab at weeks 0,
2, 6, 14 and 22. The determination of the values of CRP and
ESR, as well as the counting of 28 painful or swollen joints,
was performed at the same intervals. The European League
Against Rheumatism (EULAR) criteria15 were used to classify
the response to treatment as good (n = 5), moderate (n = 8) and
non-responders (n = 3). PET studies of metacarpophalangeal
joints and wrists were performed before the treatment and
after two weeks. The results showed that the change in SUV
between zero and two weeks correlated with DAS28 at weeks
14 and 22 (r = 0.62, P <0.05; r = 0.65, P <0.01, respectively). The
change of the components of DAS28 (ESR, CRP, joint counting,
visual analogue scale) in the interval of two weeks did not
correlate with DAS28 at weeks 14 and 22. A logistic regression
analysis showed that SUV reduction was the only signiﬁcant
predictive factor for determining DAS28 at weeks 14 and 22
( = 0.62, P < 0.05;  = 0.65, P < 0.01, respectively). The results
obtained in this small group of patients suggest that 18F-
FDG PET of wrists and metacarpophalangeal joints, performed
with only two weeks of treatment, can predict the systemic
response to inﬂiximab after 14 and 22 weeks. Considering
the high cost of this treatment, this study encourages new
research projects using 18F-FDG PET as a tool to determine
which patients may beneﬁt from the long-term treatment with
inﬂiximab, saving a lot of money for health systems, consider-
ing such a costly treatment. This strategy also could provide to
non-responders to inﬂiximab the chance of a treatment with
other biological DMARDs.
The therapeutic effects of acupuncture in the treatment
of patients with RA have also been under investigation. Sato
et al.28 included only six patients in their research. All of them
reported improvement in pain, functional capacity and qual-
ity of life after two months of treatment with acupuncture.
However, 18F-FDG PET showed no change in the metabolic
activity of the affected joints. The inﬂammatory activity
tests (CRP and ESR) did not show signiﬁcant variation after
acupuncture. These results suggest that acupuncture has no
anti-inﬂammatory effect in patients with RA.
Conclusions
Although the number of studies on the role of 18F-FDG PET in
RA is limited, and considering the small number of patients
enrolled by most studies published with this purpose, the
data presented in this review allows us to make some con-
18siderations. F-FDG PET is a non-invasive imaging method of
diagnosis which is able to demonstrate disease activity in a
straightforward and objective manner, with good correlation
with the composite activity indices used in clinical practice.
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ts high cost can be evaluated in a relative manner, when we
onsider that this is an assessment of the whole body, allow-
ng the study of all joints at once. Its ability to determine
nd predict earlier the response to treatment with biologic
MARDs constitutes a factor that deserves a more  profound
nalysis in future investigations. New prospective longitudi-
al randomized studies are needed to consolidate this method
f diagnostic imaging.
Although the actual role of this new technique in the
nvestigation of RA is not yet established, 18F-FDG PET is a
romising tool for the determination of disease activity and
n the assessment and prediction of treatment response in
atients with RA. It might be that in the future, 18F-FDG
ET will play a more  important role in the diagnosis and
ssessment of disease activity.
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